PDS Biotechnology (PDSB) Projected to Post Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect PDS Biotechnology to post earnings of ($0.31) per share for the quarter.

PDS Biotechnology Price Performance

PDSB opened at $1.37 on Tuesday. The stock’s 50-day moving average price is $1.42 and its 200 day moving average price is $2.20. PDS Biotechnology has a 12-month low of $1.13 and a 12-month high of $4.92. The firm has a market cap of $52.32 million, a price-to-earnings ratio of -1.18 and a beta of 1.68. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55.

Wall Street Analyst Weigh In

Several research analysts have recently commented on PDSB shares. B. Riley lowered their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, November 25th. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a report on Thursday, March 13th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.